Search clinical trials for: Human growth hormone

Total 31844 results

Celgene

Completed

A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea

Multiple Myeloma

Korea, Republic of
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Millennium Pharmaceuticals... and other collaborators

Completed

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene Corporation

Completed

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Allergan

Completed

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Choroidal Neovascularization | Age-Related Maculopathy

United States, Australia, Philippines
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
Starton Therapeutics, Inc

Recruiting

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Multiple Myeloma

United States
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (PLYCOM)

Multiple Myeloma

Korea, Republic of, Australia, Spain, France, Poland
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi

Recruiting

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (IsAMYP)

AL Amyloidosis

France
Amgen

Terminated

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia, Japan, Germany, Netherlands, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Multiple Myeloma | Relapsed/Refractory

United States
Karyopharm Therapeutics Inc

Withdrawn

Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (SLAM)

Multiple Myeloma
AbbVie

Terminated

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Germany, Spain
University College, London

Completed

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (LenD)

Chronic Lymphocytic Leukemia

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C)

Central Retinal Vein Occlusion | Macular Edema | Visual Impairment

Germany, United Kingdom, Hungary, Poland
University of Sydney
National Health and Medical Research Council, Australia

Completed

Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Diabetic Retinopathy | Macular Edema

Australia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Austrian Forum Against Cancer

Unknown

Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure

Multiple Myeloma Light Chain Induced Renal Insufficiency

Austria, Czech Republic
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Virginia Mason Hospital/Medical Center

Unknown

Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Prostate Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency

Growth Hormone Deficiency

France
Dong-A University Hospital
Amgen

Not yet recruiting

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Peking Union Medical College Hospital

Recruiting

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Rosai-Dorfman Disease

China
Universitätsklinikum Hamburg-Eppendorf

Active, not recruiting

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Multiple Myeloma

Germany
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
Texas Retina Associates
The Emmes Company, LLC

Completed

One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)

Diabetic Macular Edema

United States
European Myeloma Network
University of Turin, Italy

Completed

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (CPD)

Multiple Myeloma

Italy
Ciusss de L'Est de l'Île de Montréal
Celgene; C3i Center Inc.

Active, not recruiting

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Multiple Myeloma | Relapsed Hematologic Malignancy

Canada
Celgene

Completed

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma (PrObe-L)

Multiple Myeloma

Portugal
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
Amgen

Terminated

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.

Withdrawn

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Multiple Myeloma
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
North Toronto Eye Care Laser and Eye Specialists
Allergan

Terminated

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema (COLLIDE)

Diabetic Macular Edema

Canada
IRCCS Policlinico S. Matteo

Completed

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Primary Amyloidosis of Light Chain Type

Italy
Peking Union Medical College Hospital
Celgene Corporation

Completed

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

POEMS Syndrome

China
National Cancer Institute (NCI)

Completed

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
Ludwig-Maximilians - University of Munich

Completed

Dexamethasone-implant for the Treatment of RVO

Macular Edema Caused by Retinal Vein Occlusion

Germany
Istituto Clinico Humanitas

Unknown

The Treatment of Lenalidomide in Patients With POEMS Syndrome

POEMS Syndrome

Italy
EMD Serono

Completed

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

Infertile Women Undergoing Assisted Reproductive Technology (ART)
University of Aarhus

Completed

Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.

Diabetes Mellitus Type I | Ketoacidosis

Denmark
Oregon Health and Science University

Withdrawn

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

Metabolic Syndrome

United States
GeneScience Pharmaceuticals Co., Ltd.
Huazhong University of Science and Technology

Completed

Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children (Phase 1)

Growth Hormone Deficiency
Jesper Kjaergaard

Completed

GLP-1 Analogs for Neuroprotection After Cardiac Arrest (GLIP1)

Cardiac Arrest | Coma

Denmark
Massachusetts General Hospital

Completed

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease (NAFLD)

United States
University of Utah
Genentech, Inc.

Withdrawn

Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids (SURFING)

Uveitis | Macular Edema

United States
Organon and Co

Withdrawn

An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)

Infertility

3

Subscribe